Drug Profile
Research programme: selective estrogen receptor modulators - Bionovo
Alternative Names: BN-AA-003-NY; BN-AM-008-XG; BN-AO-014; BN-CB-045; BN-DF-037; BN-ES-022; BN-EU-036; BN-GU-005-DHP; BN-OB-026; BN-PC-049-BK; BN-RP-006-OHALatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bionovo
- Class
- Mechanism of Action Estrogen receptor beta agonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Female sexual dysfunction; Joint disorders; Menopausal syndrome; Metabolic syndrome; Obesity; Postmenopausal osteoporosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-syndrome(Prevention) in USA
- 12 Mar 2012 No development reported - Preclinical for Breast cancer in USA (unspecified route)
- 12 Mar 2012 No development reported - Preclinical for Colorectal cancer in USA (unspecified route)